Kwality Pharmaceutical Ltd has received registration for Bleomycin 15 1U in Mexico for sale and distribution.

Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally.

The projected business potential is around US$ 1 million in the first year, and supplies will commence before the end of Q2FY26

Kwality Pharmaceuticals remains committed to expanding access to high-quality medicines across global markets.